Attach to Form 990 or Form 990-EZ.
Information about Schedule A (Form 990 or 990-EZ) and its instructions is at www.irs.gov/form990.
| (i)Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 9 above or IRC section (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
| Total | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2010 | (b) 2011 | (c) 2012 | (d) 2013 | (e) 2014 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") .... | 73,823,292 | 41,644,804 | 67,271,113 | 74,310,661 | 91,256,682 | 348,306,552 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf....... | 0 | |||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | 0 | |||||
| 4 | Total. Add lines 1 through 3 | 73,823,292 | 41,644,804 | 67,271,113 | 74,310,661 | 91,256,682 | 348,306,552 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | 19,638,135 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 328,668,417 | |||||
Calendar year
(or fiscal year beginning in) ![]() |
(a) 2010 | (b) 2011 | (c) 2012 | (d) 2013 | (e) 2014 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 73,823,292 | 41,644,804 | 67,271,113 | 74,310,661 | 91,256,682 | 348,306,552 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 2,954,194 | 2,311,932 | 2,888,204 | 7,196,139 | 10,415,818 | 25,766,287 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 18,635 | 220,423 | 225,566 | 255,201 | 164,499 | 884,324 |
| 11 | Total support Add lines 7 through 10. | 375,043,249 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2010 | (b) 2011 | (c) 2012 | (d) 2013 | (e) 2014 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose...... | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513.. | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 6 | Total. Add lines 1 through 5. | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons... | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2010 | (b) 2011 | (c) 2012 | (d) 2013 | (e) 2014 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e | Discount claimed for blockage or other factors (explain in detail in Part VI): | |||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 1-1/2% of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by .035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| 7 | Check here if the current year is the organization's first as a non-functionally-integrated Type III supporting organization (see instructions) | |||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | ||
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
||
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | ||
| 4 Amounts paid to acquire exempt-use assets | ||
| 5 Qualified set-aside amounts (prior IRS approval required) | ||
| 6 Other distributions (describe in Part VI). See instructions | ||
| 7Total annual distributions. Add lines 1 through 6. | ||
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
||
| 9 Distributable amount for 2014 from Section C, line 6 | ||
| 10 Line 8 amount divided by Line 9 amount | ||
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2014 |
(iii) Distributable Amount for 2014 |
|
|---|---|---|---|---|
|
1
Distributable amount for 2014 from Section C, line 6 |
||||
|
2
Underdistributions, if any, for years prior to 2014 (reasonable cause required--see instructions) |
||||
| 3 Excess distributions carryover, if any, to 2014: | ||||
| a From 2009.......X | ||||
| b From 2010.......X | ||||
| c From 2011.......X | ||||
| d From 2012.......X | ||||
| e From 2013....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2014 distributable amount | ||||
|
i
Carryover from 2009 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from 3f. | ||||
| 4Distributions for 2014 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2014 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from 4. | ||||
|
5
Remaining underdistributions for years prior to 2014, if any. Subtract lines 3g and 4a from line 2 (if amount greater than zero, see instructions) |
||||
|
6
Remaining underdistributions for 2014. Subtract lines 3h and 4b from line 1 (if amount greater than zero, see instructions) |
||||
|
7 Excess distributions carryover to 2015. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a From 2010.......X | ||||
| b From 2011.......X | ||||
| c From 2012.......X | ||||
| d From 2013....... | ||||
| e From 2014....... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Information about Schedule O (Form 990 or 990-EZ) and its instructions is at| Return Reference | Explanation |
|---|---|
| ORGANIZATION'S MISSION | FORM 990, PART III, LINE 1 THE MISSION OF THE LABORATORY IS TO DISCOVER PRECISE GENOMIC SOLUTIONS FOR DISEASE AND EMPOWER THE GLOBAL BIOMEDICAL COMMUNITY IN THE SHARED QUEST TO IMPROVE HUMAN HEALTH. TO ACCOMPLISH THIS MISSION THE LABORATORY 1) CONDUCTS BASIC BIOMEDICAL RESEARCH TO INCREASE THE KNOWLEDGE OF DEVELOPMENT, GROWTH, REPRODUCTION, PHYSIOLOGICAL, AND GENETICALLY DETERMINED AILMENTS THROUGH RESEARCH WITH GENETICALLY DEFINED EXPERIMENTAL ANIMALS; 2) CONDUCTS TRANSLATIONAL BIOMEDICAL RESEARCH TO IDENTIFY THE GENOMIC BASIS FOR HUMAN DISEASE, PROMOTE THE ESTABLISHMENT OF MORE PRECISE, TARGETED THERAPIES, AND OFFER CUTTING EDGE GENOMIC DIAGNOSTICS TO THE MEDICAL COMMUNITY; 3) TRAINS AND EDUCATES SCIENTISTS, PHYSICIANS, AND OTHER PROFESSIONALS IN THESE AREAS; AND 4) PROMOTES SCIENTIFIC DISCOVERY THROUGH THE PROVISION OF MOUSE MODELS OF HUMAN DISEASE AND THE PROVISION OF RESEARCH AND CLINICAL SERVICES TO THE GLOBAL SCIENTIFIC AND MEDICAL COMMUNITY. THE LABORATORY ALSO WORKS TO ACCELERATE THE TRANSLATION OF DISCOVERIES MADE IN BASIC RESEARCH TO TREATMENTS FOR HUMAN DISEASE. |
| PROGRAM SERVICES | FORM 990, PART III, LINE 4A-4C 4A. GENETIC RESOURCES AND SERVICES ACCOMPLISHMENTS JAX PROVIDES THE SCIENTIFIC COMMUNITY WITH MOUSE GENETIC RESOURCES, RELATED TECHNOLOGIES, AND INFORMATION THAT SUPPORTS THEIR USE. THIS INCLUDES CONDUCTING PEER-REVIEWED, RESOURCE-GENERATING RESEARCH AND MANAGING THE MOUSE REPOSITORY, A COLLECTION OF OVER 7,000 UNIQUE STRAINS, MANY OF WHICH ARE AVAILABLE ONLY FROM JAX. JAX DEVELOPS MOUSE MODELS FOR HUMAN DISEASE, BEGINNING WITH DISCOVERIES OF SPONTANEOUS MUTANTS FROM JAX PRODUCTION COLONIES AND INCLUDING THE OPTIMIZATION OF MODELS ACQUIRED BY THE REPOSITORY. THIS EFFORT INCLUDES ENGINEERING NEW MODELS FOR OUR OWN HYPOTHESIS-DRIVEN RESEARCH. DURING 2014 THE LABORATORY CREATED NEW MODELS WHICH INCLUDED 15 FOR PEDIATRIC CONGENITAL HEART DISEASE AND 2 TRANSGENIC MODELS FOR PARKINSON'S DISEASE. JAX HAS A PILOT PROJECT TO USE CRISPR/CAS9 TECHNOLOGY FOR SELECTED TARGET GENES AT SCALE, PROVIDING KEY OPERATIONAL DATA TO ASSESS THE FEASIBILITY OF INCORPORATING SITE-SPECIFIC NUCLEASE TECHNOLOGY INTO THE NEXT PHASE OF THE PROGRAM. IN ADDITION SMALLER SCALE PILOT EXPERIMENTS OPTIMIZE NON-ROUTINE GENETIC ENGINEERING, INCLUDING THE CREATION OF HUMAN DISEASE ALLELES, CONDITIONAL ALLELES AND REPORTER KNOCK-INS. JAX ACHIEVED AN 85% SUCCESS RATE FOR INJECTION ATTEMPTS SCREENED; BY COMPARISON TRADITIONAL METHODS HAVE AN AVERAGE 57% SUCCESS RATE. THE MOUSE MUTANT RESOURCE (MMR) IS THE JACKSON LABORATORY'S PRIMARY REPOSITORY FOR THE ACQUISITION AND CHARACTERIZATION OF MICE CARRYING SPONTANEOUS, DISEASE-CAUSING MUTATIONS. IN 2014 FIFTY-FIVE (55) OVERLAPPING STRAINS HAVE BEEN GENETICALLY MAPPED AND ANALYZED BY WES. TWENTY-ONE (21) IDENTIFIED MUTATIONS WERE VALIDATED OVER THE LAST YEAR AND, SEVENTEEN (17) WERE CLASSIFIED AS NEW ALLELES OF GENES WITH PRIOR EXISTING MUTATIONS. FOUR (4) WERE CLASSIFIED AS MUTATIONS IN GENES FOR WHICH NO PHENOTYPE-CAUSING VARIANT HAD PREVIOUSLY BEEN OBSERVED. FINALLY, TO ASSAY SPECIFIC GENE MUTATIONS WITHIN MMR MICE AND TO MAKE NEW MMR STRAIN DEVELOPMENT KNOWN TO THE SCIENTIFIC COMMUNITY, NINETEEN (19) MOLECULAR ASSAYS WERE DEVELOPED, TWELVE (12) ONLINE PUBLICATIONS WERE POSTED TO THE MMR WEBSITE AND THIRTEEN (13) STRAINS WERE MADE PUBLIC THROUGH MOUSE GENOME INFORMATICS (MGI) DIRECT DATA SUBMISSION. WHILE JAX DEVELOPS NEW MOUSE MODELS IN HOUSE, THE REPOSITORY'S MAJOR SOURCE OF NEW MOUSE STRAINS IS THE STRAIN ACQUISITION PROGRAM. ACQUISITION ADDED APPROXIMATELY 600 STRAINS IN 2014, INCREASING THE SIZE OF THE JAX COLLECTION TO OVER 7,800 INDIVIDUAL MOUSE LINES. A KEY COMPONENT OF THE ACQUISITION PROCESS IS THE WORK DONE BY A TEAM OF CURATORS WHO ARE RESPONSIBLE FOR INTERACTING WITH DONATING LABORATORIES TO OBTAIN TECHNICAL INFORMATION AND ARRANGE IMPORTATION. CURATORS ASSIMILATE INFORMATION FROM DONATING RESEARCHERS AND PUBLISHED LITERATURE TO COMPOSE A "USER MANUAL" FOR EACH LINE. THIS INFORMATION IS ADDED TO THE JAXMICE CATALOGUE FOR USE BY THE SCIENTIFIC COMMUNITY. JAX OFFERS ONE OF THE MOST EXTENSIVE AND DIVERSE MOUSE RESOURCES IN EXISTENCE, ALLOWING US TO SUPPORT A WIDE ARRAY OF RESEARCH AND TO PRESERVE STRAINS THAT OTHERWISE MIGHT BE LOST. THE JAX CRE REPOSITORY IS AN INTEGRATED EFFORT TO GENERATE, CHARACTERIZE AND DISTRIBUTE CRE DRIVER TOOL STRAINS TO THE SCIENTIFIC COMMUNITY. THESE STRAINS ALLOW SCIENTISTS TO GENERATE PRECISE GENE DELETIONS IN A SPECIFIC ORGAN AT A SPECIFIC TIME. THE JAX CRE REPOSITORY CURRENTLY COMPRISES OVER 300 OF THESE STRAINS THAT COMPLEMENT OUR COLLECTION OF >500 "KNOCKOUT READY" STRAINS. WE EMPLOY A COMPREHENSIVE, HIGH-THROUGHPUT CRE DRIVER STRAIN CHARACTERIZATION PIPELINE, WHICH INCLUDES TWO EMBRYONIC AND TWO POSTNATAL TIME POINTS, TO PROVIDE EXTENDED FUNCTIONAL DATA FOR END USERS. ALL IMAGE AND ANNOTATION DATA IS AVAILABLE THROUGH OUR WEBSITE AND A NEW DATABASE DEVELOPED BY MGI AT JAX, CREPORTAL.ORG. THE CRE REPOSITORY WEBSITE IS ONE OF THE MOST HEAVILY VISITED SECTIONS OF ALL JAX WEBSITES, WITH OVER 120,000 PAGEVIEWS PER YEAR. CHARACTERIZATION DATA WEBPAGES SEE ESPECIALLY HEAVY TRAFFIC, DEMONSTRATING THAT THIS VALUE-ADDED INFORMATION IS BEING ACTIVELY EMPLOYED BY CRE MOUSE USERS. A MAJORITY OF THE STRAINS PRODUCED BY THE KNOCKOUT MOUSE PROJECT (KOMP2) AND INTERNATIONAL PHENOTYPING PROGRAMS CAN BE MODIFIED BY CRE TOOL STRAINS, SO THE LABORATORY IS WORKING TO ALIGN THE JAX CRE REPOSITORY WITH THIS EFFORT. TWO PROJECTS TOWARDS THIS END ARE UNDERWAY. THE FIRST LEVERAGES THE CAPACITY OF THE JAX KOMP2 PHENOTYPING CENTER TO DETERMINE IF POPULAR CRE STRAINS DISPLAY POTENTIALLY CONFOUNDING PHENOTYPES. THIS SET OF STRAINS COMPRISES THOSE WITH HIGH DISTRIBUTION HISTORY AND OTHERS OF SPECIFIC INTEREST. TEN STRAINS HAVE COMPLETED TESTING AND DATA ANALYSIS IS UNDERWAY. THE SECOND PROJECT IS BACKCROSSING AN OVERLAPPING SET TO C57BL/6NJ, PROVIDING A COMPLEMENTARY RESOURCE ON THE SAME GENETIC BACKGROUND AS THE KOMP2 RESOURCE. THE PRODUCTION GOAL IS TO PRODUCE 833 NEW STRAINS TO THE JAX KOMP2 PHENOTYPING PROJECT AND IN 2014 PASS THE 75% MARK WITH OVER 695 NEW KNOCK OUT MICE. KNOCKOUT MOUSE EMBRYONIC PHENOTYPING PIPELINE - UP TO ONE THIRD OF KNOCKOUT MICE GENERATED AS PART OF THE KOMP2 PROGRAM ARE PREDICTED TO BE EMBRYONIC LETHAL. UNDERSTANDING THE CAUSES OF EMBRYONIC LETHALITY CANNOT BE CAPTURED BY AN ADULT MOUSE PHENOTYPING PARADIGM, YET WOULD PROVIDE TREMENDOUS INSIGHT INTO GENE FUNCTION. SUBSEQUENT DETAILED ANALYSIS PROMISES TO SHED LIGHT ON THE GENES AND PROCESSES THAT, WHEN ALTERED, ARE RESPONSIBLE FOR HUMAN BIRTH DEFECTS. PRE- OR PERINATAL DEATH CAN RESULT FROM A WIDE VARIETY OF DEFECTS AT VARIOUS STAGES DURING GESTATION; HOWEVER THESE CLUSTER AT SEVERAL CRITICAL TIME POINTS WHICH CAN BE USED TO BUILD AN EFFICIENT CHARACTERIZATION SCHEME FOR HIGH THROUGHPUT PROGRAMS SUCH AS KOMP2. WORKING WITH THE INTERNATIONAL MOUSE PHENOTYPING CONSORTIUM (IMPC), WE HAVE DEVELOPED A STANDARDIZED EMBRYONIC LETHAL PHENOTYPING PIPELINE THAT MAXIMIZES THE NUMBER OF PHENOTYPES SCORED IN AN EFFICIENT, COST-EFFECTIVE MANNER. IN ADDITION TO GROSS ASSESSMENT AND EXPERT THIS INCLUDES HIGH RESOLUTION, THREE-DIMENSIONAL IMAGING AT MULTIPLE STAGES OF DEVELOPMENT. EVALUATION OF PHENOTYPES, THIS WORK WILL COMPLEMENT AND EXTEND THE CATALOGUE OF MOUSE PHENOTYPE DATA PROVIDED BY THE KOMP2 PROGRAM. TOOLS FOR STUDYING PARENT-OF-ORIGIN EFFECTS IN TURNER AND DOWN SYNDROMES - IN COLLABORATION WITH THE UNIVERSITY OF CONNECTICUT, JAX DERIVED A PANEL OF MOUSE EMBRYONIC STEM CELLS FROM TWO MOUSE MODELS OF TURNER SYNDROME; JAX#001529 C3H/HESN-PAF/J ('PAF') AND JAX#00919 IN(X)1X/J ('INX'). TURNER SYNDROME IS A GENETIC CONDITION CAUSED BY A COMPLETE OR PARTIAL ABSENCE IN FEMALES OF THE SECOND X CHROMOSOME (MONOSOMY). AFFECTED XO FEMALES SUFFER FROM A VARIETY OF DEVELOPMENTAL DISABILITIES INCLUDING GONADAL DYSGENESIS, SHORT STATURE, HEART DEFECTS AND LEARNING DISABILITIES. THERE IS EVIDENCE THAT THE ORIGIN OF THE SINGLE X CHROMOSOME IN XO FEMALES HAS AN IMPACT ON CERTAIN FEATURES OF THE DISEASE. FOR EXAMPLE, A MATERNALLY INHERITED X CHROMOSOME (XM) IS ASSOCIATED WITH MORE ADVANCED SOCIAL IMPAIRMENT AND AUTISM. DEPENDING ON THE GENETIC CROSS, PAF AND INX MICE CAN BE USED TO GENERATE XMO OR XPO OFFSPRING. JAX TOOK ADVANTAGE OF THIS TO CREATE XMO AND XPO ES CELL LINES THAT CAN BE USED TO STUDY THE MECHANISM OF PARENT-OF-ORIGIN EFFECTS AND THEIR IMPACT ON IN VITRO DIFFERENTIATED NEURONAL LINEAGES.SIMILARLY, JAX ALSO DERIVED MES CELLS FROM A MOUSE MODEL OF DOWN SYNDROME, TS65DN, WHICH CARRIES THREE COPIES OF THE REGION OF MOUSE CHROMOSOME 16 THAT IS HIGHLY CONSERVED AND HYPOTHESIZED TO BE HOMOLOGOUS WITH HUMAN CHROMOSOME 21. DOWN SYNDROME IS DUE TO THE PRESENCE OF AN EXTRA COPY OF CHROMOSOME 21 (TRISOMY 21), AND THE PARENTAL ORIGIN OF THE THIRD CHROMOSOME CAN HAVE AN IMPACT ON THE DISEASE; FOR EXAMPLE, INDIVIDUALS WITH A MATERNALLY DERIVED CHROMOSOME 21 HAVE MORE SEVERE CONGENITAL HEART DEFECTS. TO CREATE A SET OF IN VITRO TOOLS FOR THE STUDY OF PARENT-OF-ORIGIN EFFECTS, JAX GENERATED MOUSE ES CELL LINES WITH PATERNALLY DERIVED TS65DN CHROMOSOMES AS WELL AS MATERNALLY DERIVED TS65DN CHROMOSOMES. THESE ES CELLS CAN BE USED TO STUDY THE UNDERLYING MECHANISMS OF PARENT-OF-ORIGIN EFFECTS IN THE CONTEXT OF DOWN SYNDROME, PARTICULARLY IN IN VITRO DIFFERENTIATED CARDIOMYOCTES. INFORMATICS - ONE OF THE GOALS OF JAX IS TO PROVIDE INFORMATION TO SUPPORT THE USE OF MOUSE MODELS IN BIOMEDICAL RESEARCH. TO THIS END, JAX CURATES THE JAXMICE DATABASE WHICH CONTAINS A "STRAIN DATASHEET" FOR EACH JAX STRAIN INCLUDING A STRAIN DESCRIPTION, GENE AND ALLELE INFORMATION, RESEARCH APPLICATIONS, AND A LIST OF PUBLICATIONS DESCRIBING THE MOUSE, AS WELL AS LINKS TO GENOTYPING PROTOCOLS, HEALTH REPORTS, AND ADDITIONAL INFORMATION IN MOUSE GENOME INFORMATICS (MGI), PUBMED, AND OTHER WEB RESOURCES. JAX ALSO PROVIDES TECHNICAL INFORMATION ON WEB PAGES HIGHLIGHTING JAX RESOURCES BY RESEARCH OR DISEASE AREA. GIVEN THE STEADY ACQUISITION OF NEW STRAINS, WE ARE CONTINUALLY ADDING NEW DATASHEETS AND UPDATING WEBPAGES TO REFLECT NEW RESOURCES AVAILABLE. AS |
| FORM 990 REVIEW PROCESS | FORM 990, PART VI, SECTION B, QUESTION 11A THE AUDIT COMMITTEE OF THE JACKSON LABORATORY'S BOARD OF TRUSTEES REVIEWS A DRAFT COPY OF THE IRS FORM 990 BEFORE IT IS PROVIDED TO THE BOARD OF TRUSTEES. AFTER THE AUDIT COMMITTEE'S REVIEW, THE IRS FORM 990 IS FINALIZED AND PROVIDED TO THE BOARD OF TRUSTEES AND FILED. |
| CONFLICT OF INTEREST POLICY | FORM 990, PART VI, SECTION B, QUESTION 12C THE JACKSON LABORATORY PROVIDES ALL OFFICERS, BOARD MEMBERS AND KEY EMPLOYEES WITH A CONFLICT OF INTEREST, CODE OF ETHICS AND DISCLOSURE FORMS AS WELL AS THE DISTRIBUTION OF ALL POLICIES REGARDING THE CONFLICT OF INTEREST AND CODE OF ETHICS. THIS PROCESS IS DONE ANNUALLY. THE DISCLOSURE AND COMPLIANCE ATTESTATIONS ARE RETURNED TO THE GENERAL COUNSEL, WHERE THEY ARE RECORDED AND TALLIED FOR COMPLETENESS. DISCLOSURES, AS WELL AS ANY FOLLOW UP QUESTIONS, ARE ROUTED THROUGH GENERAL COUNSEL, AND IF NECESSARY THE AUDIT COMMITTEE. |
| COMPENSATION POLICY | FORM 990, PART VI, SECTION B, QUESTION 15B THE COMPENSATION AND HUMAN RESOURCES COMMITTEE OF THE BOARD OF TRUSTEES SETS COMPENSATION AND BENEFITS FOR THE CHIEF EXECUTIVE OFFICER, EXECUTIVE VICE PRESIDENT AND CHIEF OPERATING OFFICER, THE VICE PRESIDENT OF RESEARCH, THE VICE PRESIDENT OF EXTERNAL AFFAIRS AND STRATEGIC PARTNERSHIPS, THE CHIEF FINANCIAL OFFICER AND EQUIVALENT POSITIONS AS WELL AS ANY OTHER EMPLOYEES OF THE LABORATORY WHO WOULD BE CONSIDERED 'INSIDERS' OR 'DISQUALIFIED PERSONS' WITHIN THE MEANING OF THE INTERMEDIATE SANCTIONS RULES UNDER THE INTERNAL REVENUE CODE. MEMBERS OF THE COMMITTEE ARE INDEPENDENT TRUSTEES SELECTED BY THE CHAIR OF THE BOARD OF TRUSTEES. THE COMMITTEE IS GUIDED BY MARKET DATA OF COMPENSATION PACKAGES FOR SIMILAR POSITIONS IN COMPARABLE ORGANIZATIONS. MARKET DATA IS PREPARED FOR THE COMMITTEE BY AN EXTERNAL EXECUTIVE COMPENSATION FIRM WHICH CONSIDERS COMPENSATION INFORMATION REPORTED IN FORM 990'S OF COMPARABLE ORGANIZATIONS AND THE RESULTS OF RECOGNIZED COMPENSATION SURVEYS. THE SENIOR DIRECTOR OF HUMAN RESOURCES IS AVAILABLE TO THE COMMITTEE TO PROVIDE ANY OTHER DATA NEEDED. THE CEO MEETS WITH THE COMMITTEE AT LEAST ANNUALLY TO PROVIDE THE COMMITTEE MEMBERS WITH ANNUAL PERFORMANCE REVIEWS OF HIS REPORTS. THE COMMITTEE'S REVIEW PROCESS AND RESULTS ARE DOCUMENTED IN MINUTES OF THE MEETINGS. |
| PUBLIC DISCLOSURE | FORM 990, PART VI, SECTION C, QUESTION 19 THE ORGANIZATION'S FORM 990 IS AVAILABLE ON WWW.GUIDESTAR.ORG AND ON THE ORGANIZATION'S PUBLIC WEBSITE WWW.JAX.ORG. THE ORGANIZATION'S CONFLICT OF INTEREST POLICY IS ALSO AVAILABLE WWW.JAX.ORG. |
| OTHER CHANGES IN NET ASSETS | FORM 990, PART XI, LINE 9 UNREALIZED LOSS ON INTEREST RATE SWAPS (1,461,708) CHANGES IN ACTUARIAL ASSUMPTIONS 79,795 FAIR MARKET VALUE ADJUSTMENT ON LOANS 41,837,090 TOTAL 40,455,177 |
| SECURED MORTGAGES AND NOTES PAYABLE | FORM 990, PART X, LINE 23 REPAYMENT TERMS THE CT INNOVATIONS LOANS WILL BE FORGIVEN IF AND WHEN THE LABORATORY MEETS AN EMPLOYMENT GOAL OF AT LEAST 300 EMPLOYEES LOCATED IN CONNECTICUT FOR A PERIOD OF SIX MONTHS, INCLUDING A MINIMUM OF 90 SENIOR SCIENTISTS. IN ADDITION, THE AVERAGE WAGE FOR SUCH EMPLOYEES MUST EXCEED A MINIMUM TARGET LEVEL. |
| Software ID: | |
| Software Version: |